drugset / Trial / NCT01295086
Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
Completed
27 enrolled
Odense University Hospital
Aalborg University Hospital · collabAarhus University Hospital · collabRigshospitalet, Denmark · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary aim of this dose-finding study is to determine the maximum tolerated dose of taxotere, eloxatin and capecitabine (TEX) in combination with herceptin given every third week as first-line treatment in patients with HER2-positive advanced gastro-esophageal cancer. Secondary end points are to evaluate progression-free survival and overall survival.
Timeline
- Start
- 2011-03
- Primary completion
- 2014-11
- Completion
- 2018-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1250 unknown | — |
| Subject | Docetaxel | Small molecule | 42 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 51 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |